Condition
Gastric / Gastroesophageal Junction Adenocarcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 3 Gastric / Gastroesophageal Junction Adenocarcinoma clinical trials that are recruiting, at sites in 6 countries (most in China (2), United States (2), Germany (1)). By phase: Phase 3 (1), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 3Clinical trials
- 6Countries
Newest Gastric / Gastroesophageal Junction Adenocarcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer | Phase 3 | Phoenix, Arizona and 24 other locations | Recruiting | Jul 14, 2026 |
| IParomlimab and Tuvonralimab with first-line therapy for MSI-H gastric cancer | Phase 2 | Shijiazhuang, Hebei and 9 other locations | Recruiting | Aug 17, 2025 |
| Investigating OKN4395 and Pembrolizumab for Solid Tumors | Phase 1 | Beverly Hills, California and 9 other locations | Recruiting | Jan 23, 2025 |
All recruiting trials (3)
-
Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer
This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).
-
IParomlimab and Tuvonralimab with first-line therapy for MSI-H gastric cancer
This phase 2 trial tests whether adding iparomlimab or tuvonralimab to standard first-line chemotherapy and PD-1/PD-L1 therapy helps people with MSI-H, recurrent or metastatic gastric cancer.
-
Investigating OKN4395 and Pembrolizumab for Solid Tumors
This study is testing a new drug called OKN4395, alone and with another drug called pembrolizumab, to see if it can help people with solid tumors who have run out of other treatment options.
Related topics
Quick answers
How many Gastric / Gastroesophageal Junction Adenocarcinoma clinical trials are recruiting right now?
3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in China (2 trials), United States (2 trials), Germany (1 trial), Poland (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.